Q-omics provides the consensus-scored MYH15 profile across patient tissues and cancer cell-line models. MYH15 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MYH15 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, MYH15 RNA expression shows 16,456 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, COAD, and TGCT as cancer lineages where MYH15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH15 survival associations across molecular data types. MYH15 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH15 RNA expression–survival associations across cancer types. High MYH15 expression shows unfavorable associations in STAD, LAML, LUSC and UCEC, but favorable associations in SCLC and LGG. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for MYH15 RNA expression.
This table summarizes MYH15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYH15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH15 shows lower tumor expression in COAD, THCA, LUAD and READ and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher MYH15 RNA expression in normal versus tumor tissue (log2 FC = −1.087, t-test p < 0.001).
This table shows molecular features associated with MYH15 in patient tissues and cancer cell lines. In patient samples, MYH15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
